MetaVia (NASDAQ:MTVA – Get Free Report) posted its earnings results on Friday. The company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.25, FiscalAI reports.
MetaVia Trading Up 3.1%
Shares of MetaVia stock traded up $0.04 on Friday, reaching $1.34. 34,453 shares of the company were exchanged, compared to its average volume of 1,228,392. The company has a market capitalization of $6.91 million, a price-to-earnings ratio of -0.41 and a beta of 1.24. MetaVia has a one year low of $0.97 and a one year high of $13.42. The company has a 50-day moving average of $1.47 and a 200 day moving average of $1.62.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MetaVia in a research note on Monday, October 19th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, MetaVia currently has an average rating of “Hold” and a consensus target price of $20.00.
Get Our Latest Stock Report on MTVA
MetaVia Company Profile
MetaVia, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases. Its work is centered on conditions such as obesity, diabetes and other disorders associated with metabolic dysfunction. The company’s activities primarily involve the discovery, development and clinical evaluation of potential drug candidates intended to address significant unmet medical needs in metabolic health. As a development-stage biotechnology company, MetaVia’s operations are focused on research programs and advancing therapies through clinical testing rather than on commercialized products.
Read More
- Five stocks we like better than MetaVia
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.
